Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDAAA’s First Advertising Victim Is MedImmune’s FluMist

This article was originally published in The Pink Sheet Daily

Executive Summary

“Reminder” newspaper ad actually makes claims and lacks toll-free number for reporting side effects, FDA says.

You may also be interested in...



Toll-Free Number For Adverse Event Reporting Due On Labels By Mid-2009

Industry will have an extra six months - until July 1, 2009 - to comply with a requirement that drugs be dispensed with information on a toll-free number for reporting adverse events, according to a final rule on the topic issued by FDA Oct. 28

Rozerem DTC Ad Suggests Insomnia Drug Is Indicated In Children – FDA

Agency issues an "untitled" letter to Takeda citing the 10-second TV spot.

PhRMA DTC Principles Call For End Of Reminder Ads

Independent review panel will be established to handle complaints about pharmaceutical advertising.

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel